Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Beaner:
There are too many unknowns. however, it seems to me that CSBR will have to make an announcement regarding the Company since the minority interest must be reflected in the next 10-K if the Company is funded. Also, we do not know when the rights for the drug that was being tested was being transferred to the new Company. This must also be diusclosed. I, too, am concerned about the lack of disclosure and that is why i wrote the email to the C.E.O. that an announcement had to be made soon or CSBR runs the risk of current shareholders selling their stock due to a lack of information and assumptions that they are making that may be wrong.
There may be a positive spin on this in that CSBR may increase the number of drugs going through the tumorgraft platform to determine whether the drugs have any eficacy in treating cancers. This may lead to a significant increase in sales of CSBR. Perhaps management wanted to become the Company that tests all of the potential drugs for the Israeli Company.
At this point, there are simply too many unanswered questions for us to make a valid decision as to whether this will turn out to be a positive for CSBR. I specifically asked the C.E.O. to indicate why CSBR shareholders will be better off with this kind of a set-up than they would have been the other way. It could be that CSBR felt that they could not get investors who would invest sufficient funds in CSBR to take the drugs through the testing procedures since they would not get a large enough percentage of the Company for the risk that they would be taking. I suspect that pretty soon there will be full disclosure as to exactly what is going on particularly since I let the "cat out of the bag" by letting management know that we investors are aware of what is going on in Israel with CSBR but do not know the details.
The way I read it, is that every drug contract, present and future, will be passed on to the new Company. with the parent having a minority stake in the pie. But I agree it is a little confusing given the translation.
Guy Malchi will run the new Company and if I read and understood it correctly, is now done with the Parent Company.
When did this take place??
As I stated before, the lack of disclosure on this very important development is very, very concerning to me.
Once again, who are the shareholders? What Percentage does Champions have in this new company?
Very confusing........I don't like it as it stands right now. There are too many unknowns, which shouldn't be the case.
This is still a little confusing to me except that Teva is involved and that may pass on additional business for CSBR. I believe that CSBR found that drug development is simply too expensive and is using this course of action as a means of increasing revenues in CSBR as well as getting a piece of the action of drug development through a minority stake in the new Company. Still, we must have some PR announcement from management to determine exactly what is going on and the benefit that this would inure to CSBR shareholders as compared with joint ventures and royalty agreements under the old method. I believe that Sidransky has found that this method will be more lucrative for CSBR shareholders. Is the new Company a public Company for which we can buy shares? Any new thoughts on this Beamer or Milburn and thanks for your inputs.
I think this is the rest of it....again, pretty rough, but maybe you'll get an idea of what's up.
Champions of the relationship with Israel and Zionism derives in part of Sidrnsky, who currently resides in Israel as part of a sabbatical at the Weizmann Institute. Champions already has marketing operations in Israel and employs a number of employees at the branch in Ra'anana for marketing the services of her VIP patients. Like - yes, Champions signed two contracts with Teva. One, signed directly with the nature of its support in developing cancer drugs, and other potential scale of $ 27 million, was signed in front of a dish cancer drug company, Teva acquired just before it. Malhi said in an interview with Globes, that another reason for the activity in Israel is a potential support of the Chief Scientist. "The company may take advantage of the scientist development grants. Like - yes, Israel is interesting to raise capital for government support for local venture capital funds, both biomedical and general. Incubator program also interesting. We also cross-eyed toward the involvement of greenhouse - not as a project incubator but perhaps biotech incubator's franchise. But this move is currently only an initial examination ", said salts.
Furthermore, he recently invested $ 9.4 million in the company led by Battery Ventures. This support is intended to increase the activity of personality tests, pharmaceutical companies and service the VIP services. Drug development is a lengthy process more expensive and not necessarily suitable for new investors, so we set up the company - Beth.
Most companies operating in the model of service in recent years actually added elements of drug development, to make them dream. Are you going in the opposite direction.
Salts: 'Yes, but the service model and ensures stable Champions to investors, and the company will enjoy the rise in value because it has shares in the company - the daughter. I believe the greatest value lies in developing remedies.
Custom Mouse
To understand the technology of the spin - off the new, one must understand the background of Champions. The VIP service its goes like this: The company takes a sample from a patient's own tumor and planting it in dozens of mice. That, in fact, it catches them cancer. Each mouse receives a different protocol of medication, to see what is drug combination is expected to be very effective in treating the specific tumor of one patient. This major upgrade of the existing treatment of cancer, where trial and error process is the patient himself.
Future intention is to make treatment accessible to every budget. That is, use the classification of cancer in mice many different types to find out what treatment suits all of them, and then - then develop tests compiling all the growth in a human patient according to type. Champions signed contracts with nature and a dish with many other companies, based also on mice with human tumors. "We offer companies test their product on our mice collection. It's much better tried to live all of which it increased and much closer to experiment on human cancer patients.
In addition to that she had, the company has located at the University of British Columbia is a cure for cancer that develops independently, go in the first phase of clinical trials in the fourth quarter. This product flowing - Oh. "We told ourselves that if our platform knows to scan cancer therapeutics and indicate those that have a chance of success, why not do such scanning to select drugs and developed upon ourselves," says Malhi. The drug, Irinofor, based on the technology of wrapping an existing drug - Irinotecan - a layer of fat molecules. Champions studied the effectiveness of the drug on its animal model and saw that it is efficient and that side effects are few. If the drug succeeds, will it also confirmed the model of Champions itself.
Don't know if this will help you, but here is a crude translation of the first 1000 characters, via the website
http://imtranslator.net/translation/hebrew/to-english/translation/
Champions Corporation U.S. Oncology, which develops customized treatments for cancer and is traded NASDAQ Jack (Bulletin Board list) a market value of $ 32 million, establishing a spin - off Israel in the field of drug development under the name Peak - BIO (C-Bio). Learned to Globes.
This move is a novelty: no American pharmaceutical company in Israel has not established a drug development division independently, without having committed any purchase. On - the layout of the spin transaction - Oh, Champions will hold only minority shares in the company - Israeli subsidiary, joined the first phase about 3-4 million.
Champions, established - by the acclaimed cancer researcher Professor David Sidrnsky, started out providing VIP services to cancer patients. Below, has developed capabilities in classification of cancers and matching treatments to patient. Based on these capabilities is identified several new drugs, she assumed they have the potential to be very successful and effective targeted therapy of cancer of various types.
These drugs will spin - off the new, headed by Guy Malchi, Until recently Head of Pharma Division Champions.
Also due to the support scientist
Champions of the relationship with Israel and Zionism derives in part of Sidrnsky, who currently resides in the framework of...
Hi beaner:
We are assuming that Dr. Sidransky will have a personal stake in the new Company along with the C.E.O. and the president of CSBR. I think that , at this point, that is a huge assumption. Of course, we must also assume that Battery is involved in this in some way. Is this subsidiary going public or is it a private company? I still would love to see this article in english. Again, I repeat that for some time, CSBR literature has stated that they are getting out of the drug marketing and joint venture business. Take a look at their website. This is not new. Of course, what is new is that they are perhaps setting up a new Company to develop drug products and that new company will be partially owned by CSBR as a minority stake. What kind of minority stake are we talking about. I still believe that we must give management a chance to explain exactly what is going on. When will the new Company be formed and who will be funding it? there must be disclosure for SEC purposes to avoid apparent conflict of interest. If what you say is true, the management of CSBR may be treading on very thin ice. As yet, I have not seen anything that says that CSBR is transferring this valuable asset to another Company for a minority stake in that Company.
Hi Fred, I couldn't find the article in English either. But I can't think, or find any other reason they would spin this off, with the parent company (Champions) having a minority stake. Especially with Battery Ventures and more importantly Scott Tobin,(who heads the Israeli Office for Battery)on board with a substantial investment in the parent company.
Champions is protecting this Asset. If Champions get bought out, the buyer gets a minority stake in the new company. So essentially they are buying the TOS business and Personalized Oncology business, yet Sidransky and whom ever else is involved in the spinoff, retains a majority stake in the drug. Where the Real Money is.
It could simply be an Incubator Company as well. But this drug is going into Clinical Trials. As I said in a previous post, one of the biggest Pharma's in the world has a drug already on the market to target this specific cancer. If this drug comes to fruition, it will be better, much better.
Maybe I'm reading to much into this, but with the lack of disclosure, something is up.
Incidentally, Beaner, my email to Joel Ackerman was very strong indicating that management must come up with an announcement so that there will be no wrong assumptions as to the motivation of management. It was a lengthy email and I am hoping for some sort of a response. In the meantime, I will keep an open mind and assume that this move that CSBR intends to make is a positive for current shareholders in the long run. I am not being naiive on this matter. Rather, I am assuming that management would not do something so stupid as to hurt their current investors including the institutional investors since they will need money in the future. It is incumbent on us, as investors, to continue to find out more about this potential Company. Can you please refer me to the article in english that shows the information. I only saw the article in hebrew. Thanks.
I am not certain as to your analysis. For some time, CSBR has indicated that it was getting out of the joint venturing on possible new drugs that may hel;p cure cancer. I agree that the big bang in this Company was the new drug potential and partnerting with Companies that would make this happen.. There is a significant investment by an institutioanal investor (about 12 million dollars) and there is the purchase of an additional 3,000,00 shares by this institutional invetor from the original shareholder just a few weks ago. Obviously they know something that we do not know. In addition, it would be in the best interests of the president and CEO to make the stock of CSBR move upward because of their CSBR stock positions unless they will also own shares in the other Company. I do not think that any assumptions can be made here as to what the motivation of managment is without hearing from management. I believe that it would be premature to make those assumptions. As I mentioned in my previous comments, I sent an email to the C.E.O. for clarification which I believe that they will have to make in order to avoid false assumptions.
I am also at a loss to explain why management would not want to eventually be taken over. the Tumorgraft platform is very good. However, it can go so far in its ability to turn it into the golden pot at the end of the rainbow. I believe that Sidransky would eventually want to sell out and continue his consultations with a larger company. After all, he does have 11,000,00 shares in CSBR and he certainly would want to cvash that in at some point. Dr. Sidransky, from all that I can see, is a very savvy business man and i believe that he has some good motivation to do this. Incidentally, the institutional investors that invested in the Company knew that CSBR was going to downplay the future of joint ventures in drugs and still invested about 12 million dollars in the CSBR.
One could make assumptions that Sidransky will be a secret partner in the new Company along with the C.E.O. and President. However, I believe that assumption has yet to be proven and may be considered mismanagement and asset conversion.
As I said above, I believe that we must wait and not draw any possible eroneous conclusions as to what the motivation of management is regarding this matter. As you said in your email, there is much that we do not know and that hopefully management would make clear. I believe that an email from investors, other than myself, to management would help show the concern that all of us have in this matter. I absolutely agree with you on this matter that discloure is a must and I made that perfectly clear in my email to management.
Incidentally, I feel that there must be disclosure of any stake that CSBR has in another Company according to SEC rules. If they have a minority ownership in another Company that ownership would have to be reported in the financial statements. Again we know too little to make an informed decisipn, at this point, as to what is truly going on here.
It seems this may be an anti takeover strategy by the company, Hence the reason for the minority stake in the spinoff Fred. Anyway you look at it, it greatly diminishes the value of Champions Inc. when you look at it from the outside. Having said that, there are so many unanswered questions.
They will still be using the platform for their TOS services, but anybody who follows Drug and Pharma knows that New, Novel Blockbuster Drugs is where the real money is.
It concerns me that the company did this privately without any disclosure at all. Is Teva Involved with the Spin? Who are the Investors in the new Co? If Champions has a Private stake in the company, they should be disclosing it.
Is this going to be an R and D company? We all know R & D can Literally Kill small Biotech's, so this move could make Champions look leaner to new investors. Another Question that needs to be answered.
I personally think, and it is only my opinion of course, that this is an asset retainment strategy. to avoid any takeovers. This New Drug has the potential to compete with another big, HUGE, Pharma.
Disclosure is a must, this company is so well structured and managed, this is the only reason I have kept my investment in Champions.
Hi again Beaner:
I have just written an email to Joel Ackerman, C.E.O. asking him to explain why it is necessary to set up a separate subsidiary for the development of new drugs and have CSBR take only a minority interest in that subsidiary when they could probably raise the funds themselves for that subsidiary and take a majority ownership in that subsidiary. I told him that there are disgruntled investors that need an explanation as to why this is necessary. I will inform you of his response when it arriives.
Hi again Beaner:
I have just written an email to Joel Ackerman, C.E.O. asking him to explain why it is necessary to set up a separate subsidiary for the development of new drugs and have CSBR take only a minority interest in that subsidiary when they could probably raise the funds themselves for that subsidiary and take a majority ownership in that subsidiary. I told him that there are disgruntled investors that need an explanation as to why this is necessary. I will inform you of his response when it arriives.
Hi Beaner:
CSBR has indicated some time ago that it was no longer pursuing new drugs on a pertnership basis and that it was sticking to its tumorgraft technology. Apparently, they have spent too much money in trying to get new drugs started with the investments that they have made and they want to get out of that field. I do not know what minority interest that they will have in the development of these new drugs. We will have to wait and see on that one. I believe that there is a very large biotechnology company in Israel that just bought one of the Companies with whom CSBR does business. I believe that the name of that Company is Tevya and perhaps they are the ones that will be supplying the money.
It has long been my theory that CSBR will get their tumorgraft technology to a certain point and then will sell the Company. One of the interesting occurences this past year is that the original shareholder sold 3,000,000 shares of his stock to an instituitional investor. Obviously there is great interest by that institutional investor in CSBR. In addition, the President and C.E.O./Treasurer have been paid with stock as their compensation. This is an excellent way of preserving cash on the one hand and motivating management to move the stock on the other hand. It would appear to me that executives of this caliber would have to be crazy to accept an all stock compensation program if they thought that CSBR did not have a great future. In addition, I believe that it was the C.E.O. who got the institutional investors to invest.
If you eliminate the stock based compensation, CSBR lost only 0.02 this last fiscal year ended April 30, 2011 on a non-gap basis. This is a stellar performance.
I must say that I need to know more about this possible spinoff that is being planned before I can make a judgement call as to whether this is good or bad for the Company. It seems to me that CSBR is in an excellent position to determine whether a potential cancer drug has any potential to be successful through its tumorgraft technology. If so, they could then pass it on to the new spin off Company for the payment of a royalty.
Dr. Sidransky is excellent in preserving cash and in incentivising executive personnell through the issuance of stock rather than payiong them cash. One should note that CSBR has no debt to banks on its balance sheet and that it has done all of its growth through private placement of the Company stock. In addition, he has not replaced the previous Treasurer, but instead hires him out on a consulting basis to do the reporting required to the federal government such as the 10K. Once again, ,Sidransky clearly understanda the importance of maintaining cash in the Company while at the same time incentivising his employees through stock compensation.
I am a little upset over the lack of announcements as to developments in the Company. However, because of stock agreements previously made to institutional investors, I believe that Dr. Sidransky created a base below which this stock will not go for at least the short term. We must await further developments and announcements by the Comopany as to where exactly it is headed with this possible spinoff. Perhaps a letter to the C.E.O. would help obtain this information. Obviously, the Board knows what is going on, I will try to bring some pressure on Joel Ackerman through an email to make an announcement as to the details of this proposed spinoff and to let him know that some of the investors in CSBR are aware of it.
LOL, the writing is on the wall now! Unbelievable.
What do you think Fred?? Are you still around?
Beaner,
Apparently CSBR will not be using their platform to develop a drug portfolio of cancer drugs anymore. They are spinning off the division, putting Guy Malchi in charge, raising money, and will only end up with a minority position. The one drug they announced that we have and will pursue is being given over to this spinoff.
To everyone, please confirm anything and everything I've written here and previously about CSBR with CSBR before making any investment decisions.
Here the Hebrew link. I didn't check if the article is also in the Globes English edition.
http://www.globes.co.il/news/article.aspx?did=1000657895
Here's a link to the English Edition: http://www.globes.co.il/serveen/globes/nodeview.asp?fid=942
Hello Lumdus,
They are creating another subsidiary? Guy is already the head of the U.K based subsidiary, which was created a couple of years ago.
Do you have a link to that news?
Thanks
In the Israeli press, in Hebrew, it was announced that CSBR is creating a subsidiary with Guy Malchi at it's head. They are placing the one drug we have in development into the subsidiary and setting up the Company to look for additional drug candidates. They are going to raise an initial $3-$4 million dollars to fund their activities. This is all supposed to happen by the end of the year. The article said that CSBR will only own a minority stake in the new subsidiary after the raise.
CSBR needs to confirm (with a PR) or deny this information because it is material information for shareholders and potential investors.
I'd like to understand why CSBR can't create the subsidiary, raise the necessary funds, and still retain a majority stake in the Company. I'd like to know who the people are that are benefiting from the one drug we have and the drug development business model new management decided to discontinue.
I feel totally in the dark with this Company. I think it's time they worked on their shareholder relations.
I believe that CSBR stock will soar upward over the next four days. My reasonng for this belief is as follows:
1. On June 21, 2011, Battery Partners IX LLC purchased 3,000,000 shares of the Company's stock from James Martell, the previous President of CSBR.
2. Bewtween April 27 and April 29,2011 the stock of CSBR moved up approximately 22% and between May 24 and May 31, 2011, the stock of CSBR moved up about 22%. This is called institutional window dressing.
3. CSBR will soon issue its certified financial statements for the year ended April 30, 2011. These financial statements are due sometime in July, 2011 and I believe that it will show a significant increase in all categories of income over the previous fiscal year.
To my fellow investors, I say enjoy the ride up. To potentially new investors, I believe that the time to buy is right now, TODAY.
Name change effective tomorrow; ticker remains CSBR.
http://www.otcbb.com/asp/dailylist_detail.asp?d=04/19/2011&mkt_ctg=OTCBB
Another Positive Sign......
A former Executive Officer takes 8400 shares of common stock, instead of cash for severance.
No Volume = Iliquidity.............By Accredited I meant people with serious assets willing to invest in the open market..........It's not all bad though, This stock is based on pure fundamentals, not speculation, hence the stock price.
Regards,
Beaner
Hi Beaner. I do not understand your post. There has just been a 9.4 million dollar investment in CSBR which is eseentailly iliquid until there is a filing with the SEC. Again, I will repeat myself. The volume is not, in any way, high volume when compared with other companies. I have said that over and over again. However, it is high volume when compared with the history of CSBR, particularly recent history. Just go back over the volume amounts over the past year and I believe that you will find only one or two periods of 3 day volume that is the same or surpases the current volume. I have a theory about the trading of shares in CSBR. However, i will have to see the volume of trading during the upcoming months to see whether I am correct. If so, I will explain my theory at some future point.
Fred, this is not high volume. Nobody that is accredited will invest to become illiquid, that is a fact. keep touting on management, because it is needed.
Regards
Beaner
No, I would not consider 69,000 shares huge volume. What I said is that it is historically, for CSBR, huge volume. If you go back to take a look at its previous volume days you will notice that for CSBR this is high volume. In addition, because of the small float, days like this could magnify the increase. Peculiar things happen in this stock in which there is high volume. I wonder what would happen to this stock if there were seven straight days of volume of 70,000 shares or more, which for most stocks is low volume but for CSBR is high volume.
Fred,
"I would agree with you except for the fact that price swings with huge volumes do mean something. We have had historically high volume of shares traded for this stock in the past two days and yesterday all of the trades seem to have gone through on the asked side."
Do you really consider 69k shares huge volume? If your neighbor is finally listening to your advice and buying shares he could singlehandedly be the one raising the pps by 25%. Until the float increases and the price increases to where institutions can take a position and the stock can be traded I don't think you can apply normal market metrics to it. That is not to say that I don't think that the company's latest news is significant and signifies a move towards greater visibility and marketability.
I would agree with you except for the fact that price swings with huge volumes do mean something. We have had historically high volume of shares traded for this stock in the past two days and yesterday all of the trades seem to have gone through on the asked side. To me, on an historical basis, with this stock, that is very meaningful. Should this stock break through $1.20 on substantail volume, that would also be very significant. In addition, what is also significant is the amount of positive news coming from management and the greater amount of potential investors that are learning about CSBR. I do believe that there has been a definite change in the movement of the Company stock. There will always be investors that sell at market and the MM boys who will gobble them up at a rediculous price. The idiot that sold a short while ago for 0.45 must have put in a market order and obviously he did not do his due diligence. For a long time, this stock was undervalued languishing in apparent anonimty. I believe that in the past few days it has come out of its shell and, like a new debutante, is being presented to a whole new class of invetors who seem to like the "beauty" of the Company. Remember that $4.00 is management's immediate goal to get listing on the NASDAQ. We will have to see what today brings.
Fred I'm with you on the bullish expectations. However, price fluctuations at this stage do not really mean much, nor do technical indicators. Remember that this stock trades 0 shares sometimes for days on end. We might be at the stage where that changes soon, but for right now there is no real market and price swings and valuation do not really reflect true value of the co. Last week the stock even traded at 45 cents!
Good luck
As I was saying, I am tremendously bullish on CSBR which went up about 25% today. This is definitely a reflection on all of the good news that has recently been announced. Technically, this stock is in a phenomenal bullish mode and a move above $1.20 will propel this stock much higher. It should be noted that all of the trades were on the asked side which means buyers were buying and holders were not selling on the bid. Fundamentally and technically this stock is in its early stages of movement. Remember that the stock must stay in the $4.00 range for a period of time in order for it to be listed on NASDAQ. I believe that it will get there in the not too distant future. Good luck and good fortune for all of those who took my advice to buy this stock and for those who did not, it is not too late. BUY NOW.
Hi CHM. I issued my bullish projections on yahoo-finance a few days ago and I have been actively posting to the Cephelon Message Board telling them about CSBR. I am bullish long and short-term. This stock has moved up 40% in three or four days. From a technical standpoint it has plowed through its 50 day and 200 day moving trendline, has made a new high and is in the process of finishing a W formation. This is wildly bullish. I can not see why anyone would sell this stock at this point, particularly if they are long-term investors, except for the possibility of profit taking. Actually, today's move even caught me by surprise. However, if you look at the past history of this stock when it moves up, particularly when it makes new highs, it goes even higher. With such a small float, it is no wonder that this stock is soaring. Now is the time to buy and not to sell except for special circumstances.
Congrats Fred, glad that CSBR is getting some attention today.
Still hanging onto my remaining shares long term to see what happens.
best,
CHM
I just saw a significant announcement made by CSBR on Friday regarding the licensing of IRONPHORE C from the BC Cancer agency in British Columbia, Canada. The reason for the licensing was the positive results obtained from the Tumorgraft study of the compound. Phase 1 clinical studies are to begin in the fourth quarter of 2011. This compound is to be used for patients having advanced solid tumors. I believe that this is the first compound that was licensed that is going into Phase 1 Clinical study. It seems to me that this announcement is of great significance to the Company in that it is a direct indication what the Tumorgraft Platform can do for the Company in getting the Company involved with a compound that could directly help advanced cancer patients.
Interesting day of trading. Initially the stock ran to $1.09 and then apparently profit taking took place and took the stock back down to 0.85. Then there was buying that brought the stock back to 0.95. I hope that those who did the profit-taking also did their due diligence. There are simply too many positive stories, including the licensing by CSBR of one of the drugs it had been testing, to have sold this stock at this time. If people who werre sellers of this stock felt that it was a pump and dump they are absloutely wrong. On the other hand, I could see some people taking profit on a portion of their positions if they have been in csbr stock for some time. I was not a seller of the stock today since I feel that it will continue to go up in the near future (perhaps even tomorrow)because of the positive stories that have been circulating. I am indeed a long term investor and am very bullish over the short and long-term. I believe that investors do themselves and injustice if they get out of the stock now.
With the Name change, don't be surprised to see a ticker change as well.
PR from this morning...
Champions Biotechnology Changes Name to Champions Oncology
Press Release Source: Champions Oncology, Inc. On Monday April 4, 2011, 8:49 am EDT
BALTIMORE, April 4, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC:CSBR.ob - News) ("the Company") announced today that it has changed its name to Champions Oncology, Inc.
The name change reflects the Company's new strategic focus on developing advanced technologies to personalize the development and use of oncology drugs. As a result of this new focus, the Company does not currently plan to in-license any additional compounds in the future.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts™ , unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. The Company offers personalized Tumorgraft™ development, drug studies and genome sequencing as part of its Personalized Oncology Solutions ("POS") whereby physicians can evaluate the effects of cancer drugs on their patients' Tumorgrafts™ and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient. The Company's Tumorgraft™ Technology Platform is also used to provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) to leading pharmaceutical and biotechnology customers. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents and could lead to a faster and less expensive paths for drug development. TOS also includes biomarker discovery and the identification of novel drug combinations. In addition, the Company provides to oncologists and their patients expert tumor panels to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate.
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.
CHAMPIONS Oncology, Inc.
855 N. Wolfe Street, Suite 619
Baltimore, Maryland 21205 USA.
Susan Foreman
Tel. 410-369-0365
WEB SITE: www.championsoncology.com
Hi Milburn:
Thank you for your compliment. One other thing that I did not mention before. It should be noted that this Company has very little debt (mainly accounts payable) and it pays its executives with stock. Therefore, the success and motivation of these executives are directly tied into the performance of the stock. I do think that Dr. Sidransky has done a wonderful job. However, there is definitely a lack of communication in getting the word out. I leave that up to the President and C.E.O. and I believe that you will see the stock move up in the very near future as soon as more and more people realize what a good investment this is.
Thanks to you, Fred. I enjoy reading your posts and really appreciate having access to your analysis of this company. I certainly agree that they should be doing a much better job in the communication department.
Thanks Milburn. That is good news. The pink sheets simply have a very bad stigma attached to it. This news slong with the good financials and the Cephelon deal as well as the conference in Orlando where Dr. Sidransky is making a presentation bodes well for this stock next week. I certainly would not be a seller of this stock at this point particularly because it has broken out of its trading range and has crossed both the 50 and 200 day moving averages, a very bullish sign. Now, if only management would make the announcement of the fact that they are off the pink sheets it should help the stock move even higher.
Good news today....we're off the pinks.
Saw this happen recently to a few of those other stocks that got yanked back in February, so this is not surprising.
OTCBB System Changes - 4/1/2011
SECURITY ADDITIONS
CSBR Champions Biotechnology, Inc. Common Stock
Effective 4/4/2011 From NBB
http://www.otcbb.com/asp/dailylist_detail.asp?d=04/01/2011&mkt_ctg=OTCBB
This was an interesting run up today. It ran up on minimal shares. Apparently, I am looking at this Copmpany a little bit different that you fellows are. I have had conversations with the current C.E.O. and the the two past presidents, including Martell. Their main interest is to get these shares up to $4.00+ per share so that they can get listed. I agree with you, to some extent, that it looks as though they are using this stock as there own piggy bank. However, they are moving forward quickly and their last financial statements showed a NON-GAAP profit. I believe that it will be in their best interest (especially the C.E.O.) to not let this stock go below $0.75 per share. I have absolute faith in Dr. Sidransky to get the job done. I just found out that he will be a half hour away from where I live this weekend and I am trying to get a meeting with him. However, I do not think that I will be able to do it since I found out too late that the Conference that he will be attending is here. I am of a firm mind that this Company will be sold before it gets too big. I have always ,and I continue to say, that the sales price would be $10.00 per share. I am very happy to move along on the coat tails of the "piggy bankers" and hope that they will make multi- millions of dollars. The rise in this stock was very interesting and showed what a small float will do. Soon, we will have new investors in this Company and I suspect that they will test the small float and move the stock upward. However, in the final analysis, it all gets down to Dr. Sidransky as it has from the very beginning and I totally believe in his skill to move this Company forward so that all will prosper.
Still holding my original shares from 2005, which I got for 5 cents. Normally don't hold penny stocks that long, but I've always felt this was one worth waiting for. If I've waited this long, I can certainly hold on for a few more years.
GLTA!
The ones I just sold were 2 years old...paid 90 cents for them, sold at $1.01 (12% return, 6% APR) not a good return compared to other biotechs I have owned. The shares I kept I bought in 2007/2008 and have 143% return so far. Note that they are actually "freebies", because I had sold enough in 2008 to recoup 100% of my original investment.
Please realize that I am talking minimal shares here....now own only 3,000 just to keep my toe in. I'm a biotech junkie!
I don't know how long you have had your shares, but doubling your money is a pretty good investment.
FWIW, I just sold some shares I bought for 90 cents in 2009. Lousy return for 2 years, but at least I got a small gain.
I'm keeping my oldest shares (bought at 41 cents) because I'm a glutton for punishment but, until this company stops acting like a personal piggy-bank for the insiders, I don't hold out much hope for it as an investment.
Fred, I truly hope that CSBR is not your only investment and that you are diversified in other securities. I know you are a true believer, but there are many other interesting biotech companies that you could enjoy being invested in.
sincere best regards,
CHM
Perhaps an omen for the future. The current bid on CSBR stock is $0.45 per share and the current ask is $10.01. However, do not count your money yet since I think it must be a typo. But, it is nice to dream isn't it?
Thanks Beaner. I already had read it. Well, this solves any problem they may have had with cash flow, but seems to price CSBR at 0.75 per share, which is a reduction of 0.09 per share from its current level. I laugh at this for a moment since one of their first private placements that they made a few years ago was at $1.75 per share when the Company had practically nothing. Now, several years later, when the Company has its best financial statements as well as a good contract with Cephalon , the Private Placement is at $1.00 per share cheaper than it was when it had nothing but a future and no financials to it up. Perhaps the price has been kept artificially low by the new C.E.O and new President so that they and their fellow investors would be able to buy in at such a lucrative price. There will be a presentation at AACR on April 5, 2011. Perhaps, at that point, the stock will begin to move up. The one positive thing is that CSBR has grown the Company through equity capital rather than through debt. However, the valuation of the Company for the old investors has been way too low on an historical basis. The mere announcement of Dr. Sidransky as the Chairman of the Board four years ago caused the stock of CSBR to rise to $2.15 per share when the Company had nothing. We have come a long way since then. However, the stock has gone in the reverse direction. I believe that this Private Placement satisfies the requirement that the C.E.O and President raise at least $5,000,000 in Private Placement by April, 2011. Perhaps this will be the starting point for the movement upward. In addition, it is possible that the new investors will maintain the price of the stock of CSBR above 0.75 per share. I believe that they got a very sweet deal. The payoff for them, as for all of us, will come when CSBR is purchased by another Company which I am certain will happen someday.
Here you go Fred.....New 8k out
Entry into a Material Definitive Agreement, Financial Statements an
Item 1.01. Entry into a Material Definitive Agreement.
On March 24, 2011, Champions Biotechnology, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Agreement") with Battery Ventures IX, L.P. and Battery Investment Partners IX, LLC (collectively, "Battery"), Harris & Harris Group, Inc., Perceptive Life Sciences Master Fund Ltd., Porter Partners, L.P., EDJ Limited, Northwood Capital Partners, LP, The Oliver D. Curme Children's Trust - 1977, Richard L. Sandor Revocable Trust, Steve Geller, Joel Ackerman, Chief Executive Officer and a director of the Company, Dr. Ronnie Morris, President and a director of the Company, and Bernard Kaminetsky (collectively, the "Investors"), for the sale to the Investors of an aggregate 12,533,333 shares of the Company's Common Stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $0.75 per share, or an aggregate of $9,400,000. As part of the purchase, certain of the Investors received warrants to purchase an aggregate 1,010,000 shares of Common Stock at $0.90 per share (the "Warrants"). The Warrants expire five years after the closing date. Closing is expected to take place within 15 days.
The Agreement contains certain anti-dilution protections for the Investors and certain registration rights with respect to the shares of Common Stock to be issued to the Investors. Furthermore, Investors will have the right to require the Company to repurchase the purchased shares (the "Put Option") for cash for $0.75 upon a change of control or sale of substantially all of the company's assets. The Put Option will terminate upon the achievement of certain financial milestones.
Pursuant to the terms of the Agreement, the Company agreed to present one nominee nominated by Battery to become a member of the Company's Board of Directors either through an action by written consent or through the vote of the Company's stockholders at the next meeting of the Company's stockholders; provided, however, that the Company will not be obligated to present the Battery nominee in the event that Battery has sold greater than or equal to twenty-five percent (25%) of the shares of Common Stock it purchases pursuant to the Agreement.
The shares of Common Stock to be sold pursuant to the Agreement will be sold to accredited investors only in a private placement in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933 and Regulation D promulgated thereunder.
The foregoing description is qualified in its entirety by the terms of the Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference. The Company intends to use up to $1.4 million of the proceeds from the sale to purchase outstanding shares of the Company's Common Stock in one or more private transactions at a discount to the $0.75 purchase price of this financing. The balance of the proceeds will be used for general corporate purposes. The Company intends to issue a press release describing the transaction following the closing.
On March 22, 2011 Cephalon announced a merger agreement with Gemin X, A Private Biopharmaceutical Company who is into research regarding oncology drugs. The price was $225 million. I present thid since it would appear that should CSBR be successful in its tumorgraft platform analysis with Cephalon, there is the possibility of a buyout. I have long felt that CSBR would be purchased by another company as it gains success in its tumorgraft platform and as its finanancial statements continues to improve. In addition, I have read some time ago that Carl Ichan was friendly with Dr. Sidransky and liked his work. I am not, in any way, spreading any false rumors, but merely presenting information which should make one very bullish on this stock and that is further reason that the price of $0.85 per share is absurd at this point. In addition, I have said in some of my previous posts that I felt that CSBR would be bought out at $10.00 per share. I will continue to be a buyer of CSBR as long as its stock price shows improvement.
I don't think so Beaner. However, when the stock went down to .60, I contacted the C.E.O. by email and informed him of the sale. I also told him that, from an investor standpoint, considering all of the positive information in the past week, the price of .60 per share was unacceptable. I then went in and bought 100 shares of CSBR at 0.84 per share and at 2:10 P.M. someone bought 7,500 shares at 0.84 per share. I remain proactive. This is what I have done today for our stock. I ask the rest of the investors what have you done today to maintain the value of CSBR stock?
Fred is that you buying all those shares?
Followers
|
41
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2378
|
Created
|
11/27/06
|
Type
|
Free
|
Moderators |
CSBR.OB - CHAMPIONS BIOTECHNOLOGY, INC.
Website:http://www.championsbiotechnology.com/
Edgar Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=Champions+Biotechnology&CIK=0001041771&filenum=&State=&SIC=&owner=include&action=getcompany
2200 Wilson Blvd, Suite 102-316, Arlington, VA 22201
703-526-0400
Primary State of Incorporation: Delaware
James Martell, Chairman/President/CEO
James E. McCollam, Secretary
On February 14, 2007, the Registrant agreed to acquire all of the patent rights underlying pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled “Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.” The acquisition represents the commencement of the Registrant’s strategy to develop a biotechnology business based on therapeutic drug candidates among other possible ventures.
The purchase price for the patent rights consisted of an aggregate of up to 550,000 restricted shares of common stock, of which 300,000 restricted shares were issued upon execution of the acquisition agreement and 250,000 restricted shares are issuable upon the issuance of one or patents based on U.S. Patent Application no. 11/673,519. The Registrant has 27,624,658 issued and outstanding common shares and of those, 19,573,000 are restricted common shares.
On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock toDr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
David Sidransky, M.D.
http://www.cnn.com/SPECIALS/2001/americasbest/science.medicine/pro.dsidransky.html
David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award
Link to David Sidransky's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=David+Sidransky&ie=ISO-8859-1&s....
Manuel Hidalgo, M.D., Ph.D.
-Associate Professor of Oncology at the Johns Hopkins Institute.
-M.D.,University Navarra Medical School, Pamplona, Spain
-Ph.D., Infectious Diseases in Cancer, Univeristy Autonoma, Madrid, Spain
-Fellowship (Medical Oncology) University Hospital “12 de Octubre”, Madrid, Spain
-Research Fellow, University Hospital “ 12 de Octubre”, Madrid, Spain
-Clinical Research Fellow, Cancer Therapy and Research Center, San Antonio, TX
-Board Certification in Medical Oncology
-Clinical Interests: Stomach cancer, Colon and rectum cancers, Pancreas cancer, Biliary Tract cancer, Gallbladder cancer.
Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Link to Manuel Hidalgo's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=Manuel+Hidalgo&ie=ISO-8859-1&sp...
OS: 31,624,658 issued and outstanding common shares
Restricted: 23,573,000
Float: 8,051,658
Transfer Agent: Integrity Stock Transfer, Las Vegas, NV 89120
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
News Items and Filings
Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader |
BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform. By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. "We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization." About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |